Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success
Taylor Morrisette, Kyle C. Molina, Beatriz Da Silva, Scott W. Mueller, Laura Damioli, Martin Kršák, Matthew A. Miller, Douglas N. Fish
Abstract
Abstract Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62–493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated.
Topics & Concepts
TolerabilityMedicineDiscontinuationInterquartile rangeInternal medicineAdverse effectActinomycetales infections and treatmentMycobacterium research and diagnosisTuberculosis Research and Epidemiology